Treats venous thrombosis and its extension, pulmonary embolism (PE). ANDA 202202, held by Amneal Pharms. Warfarin Sodium.
As of Nov 16, 2026, ANDA 202202 (Warfarin Sodium), held by Amneal Pharms, was first approved by FDA on Mar 4, 2013, with 4 approved supplements and 0 published complete response letters.
Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 4, 2013 | Original application | Approved | None posted |
| Warfarin Sodium1MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium2MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium2.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium3MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium4MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium6MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium7.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium10MG · tablet;oral | Warfarin Sodium | Rx |
| Aug 23, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 4, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters